Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth - GBI Research Reports

Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth

Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth - GBI Research Reports
Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth
Published Sep 01, 2011
150 pages — Published Sep 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Researchs report, Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth provides in-depth analysis of the drivers and barriers that affect the global gastrointestinal disorder therapeutics market. The report analyzes the markets for gastrointestinal disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2017 for the key geographic regions as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is compiled using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Research finds that the gastrointestinal disorder therapeutics market will decline during the period 2010-2017. This decline will primarily be driven by the negative growth of the gastroesophageal reflux disease (GERD) therapeutics market, which is attributed to the loss of drug patents and the entry of generics. However, other key gastrointestinal markets, such as Crohns disease and irritable bowel syndrome therapeutics, will continue to grow due to a strong late stage pipeline that will address unmet needs. The global gastrointestinal disorder therapeutics market is a highly fragmented market, where the big players face stiff competition. The forthcoming patent expiries of major drugs have increased competition, driving the consolidation further. This increasing pressure has also driven companies to enter into licensing agreements. This allows companies to expand their product portfolios and improve their competitive positions in the market.

Scope

The scope of this report includes -
- Annualized market data for the gastrointestinal disorder therapeutics market from 2001 to 2010, and forecast to 2017.
- Analysis of the leading therapeutic segments. These include Crohns disease, ulcerative colitis, irritable bowel syndrome and gastroesophageal reflux disease.
- Analysis of the gastrointestinal disorder therapeutic markets in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the gastrointestinal disorder therapeutics market, including market size, revenue analysis by top seven geographies, generic share, annual cost of therapy, treatment flow algorithm and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of the pipeline molecules in various phases of drug development.
- Competitive benchmarking of the leading companies. The key companies studied in this report are AstraZeneca, Pfizer Inc, Abbott Laboratories, Johnson & Johnson, Salix Pharmaceuticals, Takeda Pharmaceutical Company Ltd. and Shire Plc.
- Key M&A activities and licensing agreements that have taken place between 2008 and 2011 in the global gastrointestinal disorder therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by unde

  
Source:
Document ID
GBIHC131MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents49
  List of Tables83
  List of Figures112
Gastrointestinal Disorder Therapeutics Market: Introduction132
  Overview131
  GBI Research Report Guidance141
Global Gastrointestinal Disorder Therapeutics Market: Market Characterization1511
  Market Forecasts151
    Revenue151
    Global Generic Share161
    Annual Cost of Treatment (ACT)171
    Treatment Usage Patterns182
      Diseased Population201
      Treatment Seeking Population211
      Diagnosed Population221
      Treated Population231
  Drivers and Restraints for the Global Gastrointestinal Disorder Therapeutics Market241
    Market Drivers241
      Stable Increase in the Prevalence and Incidence Rates241
      Increase in Awareness Levels of Disease Progression and Etiology241
      Future Approval and Launch of Biologics241
    Market Restraints251
      Entry of Generics and Their Dominance in the Future251
      Lack of Definite Diagnosis and Low Diagnosis Rate251
      Presence of Serious Side Effects for Certain Classes of Therapeutic Drugs251
Gastrointestinal Disorder Therapeutics Market: Geographical Landscape2616
  Revenue Analysis by Geography262
  The US281
    Revenue281
    Annual Cost of Treatment291
    Treatment Usage Patterns301
      Diseased Population311
      Treatment Seeking Population311
      Diagnosed Population311
      Treated Population311
  Top Five Countries of Europe321
    Revenue321
    Revenue by Country332
    Annual Cost of Treatment351
    Treatment Usage Pattern361
      Diseased Population371
      Treatment Seeking Population371
      Diagnosed Population371
      Treated Population371
  Japan381
    Revenue381
    Annual Cost of Treatment391
    Treatment Usage Patterns401
      Diseased Population411
      Treatment Seeking Population411
      Diagnosed Population411
      Treated Population411
Global Gastrointestinal Disorder Therapeutics Market: Therapeutic Landscape4252
  Global Irritable Bowel Syndrome Therapeutics Market Forecasts421
    Introduction421
    Revenue431
    Generic Share441
    Revenue Analysis by Country452
    Annual Cost of Treatment471
    Treatment Flow Algorithm481
    Treatment Usage Patterns491
      Diseased Population501
      Treatment Seeking Population501
      Diagnosed Population501
      Treated Population501
  Marketed Products511
    Lotronex511
      Overview511
    Amitiza (Lubiprostone)511
      Overview511
    Bentyl (Dicyclomine hydrochloride)521
      Overview521
  Drivers and Restraints for the IBS Therapeutics Market531
    Drivers for the IBS Therapeutics Market531
      Launch of New Drugs with Novel Mechanism of Action531
      High Prevalence of the Disease531
    Restraints for the IBS Therapeutics Market531
      Low Treatment Seeking Rate Could Affect the Availability of Patients for Prescription531
      Lack of Definite Diagnostic Techniques Delays Treatments of IBS531
  Global Ulcerative Colitis Therapeutics Market Forecasts541
    Introduction541
    Revenue551
    Generic Share561
    Revenue Analysis by Country572
    Annual Cost of Treatment591
    Treatment Flow Algorithm601
    Treatment Usage Patterns611
      Diseased Population621
      Treatment Seeking Population631
      Diagnosed Population631
      Treated Population631
  Major Marketed Products641
    Asacol641
      Overview641
    Lialda641
      Overview641
    Pentasa641
      Overview641
    Apriso641
      Overview641
    Colazal641
      Overview641
    Remicade651
      Overview651
    Azulfidine651
      Overview651
  Drivers and Restraints for Ulcerative Colitis Therapeutics Market651
    Drivers for the Ulcerative Colitis Therapeutics Market661
      The Future Approval of Biologics will Drive the Market661
      Availability of Large Patient Pool will Increase the Market Revenue661
    Restraints for the Ulcerative Colitis Therapeutics Market661
      Diagnostic Limitations could Affect Market Growth661
      Complex Etiology of Ulcerative Colitis Makes the Diagnosis and Treatment of the Disease Difficult661
  Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecasts671
    Introduction671
    Revenue682
    Generic Share701
    Revenue Analysis by Country712
    Annual Cost of Treatment731
    Treatment Flow Algorithm742
    Treatment Usage Patterns761
      Diseased Population771
      Treatment Seeking Population771
      Diagnosed Population771
      Treated Population771
  Major Marleted Products781
    Nexium (esomeprazole)781
      Overview781
    Aciphex (rabeprazole sodium)781
      Overview781
    Prevacid (lansoprazole)781
      Overview781
    Prilosec (omeprazole)781
      Overview781
    Protonix (pantoprazole sodium)791
      Overview791
    Tagamet (cimetidine)791
      Overview791
    Pepcid (famotidine)791
      Overview791
    Zantac (ranitidine hydrochloride)791
      Overview791
    Axid (nizatidine)791
      Overview791
  Drivers and Restraints for the GERD Therapeutics Market801
    Drivers for the GERD Therapeutics Market801
      Increase in Treatment Seeking and Diagnosed Population Drives the Market801
    Restraints for the GERD Therapeutics Market801
      Declining Annual Cost of Therapy will Obstruct Market Growth801
      Low Unmet Needs Make the Market Less Attractive801
  Global Crohn s Disease Therapeutics Market Forecasts811
    Introduction811
    Revenue821
    Generic Share831
    Revenue Analysis by Country842
    Annual Cost of Treatment861
    Treatment Flow Algorithm871
    Treatment Usage Patterns881
      Diseased Population891
      Treatment Seeking Population891
      Diagnosed Population891
      Treated Population901
  Major Marketed Products901
    Remicade (infliximab)901
      Overview901
    Humira (adalimumab)901
      Overview901
    Tysabri (natalizumab)911
      Overview911
    Entocort EC (budenoside)911
      Overview911
    Cimzia (cetrolizumab pegol)911
      Overview911
  Drivers and Restraints for the Crohn s Disease Therapeutics Market921
    Drivers for the Crohn s Disease Therapeutics Market921
      Increasing Prevalence of the Disease Drives the Market921
      Existing High Priced Drugs and Future Approval of Biologics Fuel Market Growth921
      Higher Prescription Rate will have Positive Impact on the Market in the Future921
    Restraints for the Crohn s Disease Therapeutics Market931
      Low Diagnosis Rate Acts as a Barrier for the Market931
Global Gastrointestinal Disorder Therapeutics Market: Pipeline Analysis9428
  Research and Development Pipeline by Phase941
  Research and Development Pipeline by Indication951
  Irritable Bowel Syndrome: Research and Development Pipeline961
    Overview961
    Pipeline by Clinical Phases of Development971
      Discovery971
      Preclinical971
      Phase I971
      Phase II981
      Phase III/NDA Filed981
  Promising Drugs under Clinical Development for Irritable Bowel Syndrome991
    Linaclotide (Linaclotide Acetate)991
      Overview991
      Efficacy991
      Safety991
      Clinical Study Details991
    Asimadoline1001
      Overview1001
      Efficacy1001
      Safety1001
      Clinical Trial Details1011
    Xifaxan (Rifaximin)1011
      Overview1011
      Efficacy1011
      Safety1021
      Clinical Study Details1021
  Ulcerative Colitis: Research and Development Pipeline1031
    Overview1031
    Pipeline by Clinical Phases of Development1041
      Discovery1041
      Preclinical1041
      Phase I1041
      Phase II1051
      Phase III/NDA Filed1061
  Promising Drugs under Clinical Development for Ulcerative Colitis1071
    Humira (Adalimumab)1071
      Overview1071
      Efficacy1071
      Safety1071
      Clinical Study Details1071
    Golimumab1071
      Overview1071
      Efficacy1071
      Safety1071
      Clinical Study Details1081
    Vedolizumab1081
      Overview1081
      Efficacy1081
      Safety1081
      Clinical Study Details1081
  Crohn s Disease: Research and Development Pipeline1091
    Overview1091
    Pipeline by Clinical Phases of Development1101
      Discovery1101
      Preclinical1101
      Phase I1101
      Phase II1111
      Phase III1121
  Promising Drugs under Clinical Development for Crohn s Disease1131
    Myoconda1131
      Overview1131
      Efficacy1131
      Safety1131
      Clinical Study Details1131
    Traficet-EN (CCX282)1131
      Overview1131
      Efficacy1131
      Safety1141
      Clinical Study Details1141

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth" Sep 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Gastrointestinal-Disorder-Therapeutics-Market-to-2017-Crohn-s-Disease-and-Irritable-Bowel-Syndrome-Markets-Show-Strongest-Growth-2115-251>
  
APA:
GBI Research Reports. (2011). Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth Sep 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Gastrointestinal-Disorder-Therapeutics-Market-to-2017-Crohn-s-Disease-and-Irritable-Bowel-Syndrome-Markets-Show-Strongest-Growth-2115-251>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.